http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013114376-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-463 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 2010-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013114376-A |
| titleOfInvention | APPLICATION AVE0010 FOR THE PRODUCTION OF A MEDICINE FOR TREATMENT OF TYPE 2 DIABETES |
| abstract | 1. The use of desProexendin-4 (1-39) -Lys-NHyl / or its pharmaceutically acceptable salt for the manufacture of a medicament for reducing postprandial plasma glucose concentration in patients with type 2 diabetes, where the specified patient with type 2 diabetes to be treated, has a 2-hour postprandial plasma glucose concentration of at least 14 mmol / L. 2. The use of claim 1, wherein the subject to be treated is obese. 3. The use of claim 1 or 2, wherein the subject to be treated has a body mass index of at least 30 kg / m. The use of claim 1, wherein the subject to be treated is an adult subject. The use of claim 1, wherein the subject to be treated does not receive antidiabetic treatment. The use according to claim 1, wherein the subject to be treated has been diagnosed with type 2 diabetes at least 1 year or at least 2 years before starting therapy. The use of claim 1, wherein the subject to be treated has an HbA of about 7 to about 10% .8. The use of claim 1, wherein the subject to be treated has a fasting plasma glucose concentration of at least 8 mmol / L. The use of claim 1, wherein the subject to be treated has a glucose excursion rate of at least 2 mmol / L, at least 3 mmol / L, at least 4 mmol / L, or at least 5 mmol / L, where the excursion glucose is the difference between a 2-hour postprandial plasma glucose concentration and a plasma glucose concentration 30 minutes before a meal test. 10. The use according to claim 1, wherein desProexendin-4 (1-39) -Lys-NH or / and a pharmaceutically acceptable salt thereof are administered parenterally. The use of claim 1, wherein the preparation is |
| priorityDate | 2010-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.